{"id":"W3040762243","doi":"10.1016/j.cgh.2020.07.012","title":"Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab","year":2020,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Genentech; National Institutes of Health; Bristol-Myers Squibb; Shire; Crohn's and Colitis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Tillotts Pharma; Meso Scale Diagnostics; AbbVie; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Pfizer; Sandoz; Biogen","keywords":"Medicine; Vedolizumab; Ustekinumab; Internal medicine; Gastroenterology; Inflammatory bowel disease; Inflammatory Bowel Diseases; Adalimumab; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003037537,0.0002826728,0.0007080199,0.00005075603,0.00005232719,0.000008250524,0.0002060799,0.0003914901,0.00003931331],"category_scores_gemma":[0.000483952,0.0001591149,0.000103117,0.00005146402,0.0008018878,0.00001572149,0.0001259827,0.0003111926,0.000002046349],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009428766,"about_ca_system_score_gemma":0.0002537335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004769547,"about_ca_topic_score_gemma":0.0001879794,"domain_scores_codex":[0.996732,0.001011334,0.001084649,0.0007163458,0.00009795032,0.0003577297],"domain_scores_gemma":[0.9985037,0.0001818538,0.0005062902,0.0003370614,0.000163497,0.0003076386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1546779,0.0006638211,0.8432189,0.00006666966,0.0001504279,0.0001754773,0.00001844348,0.000002753098,0.0001935968,0.00001599679,0.00004861419,0.0007674646],"study_design_scores_gemma":[0.02381624,0.01429727,0.9609255,0.00003376517,0.00007267031,0.000004468925,0.00002184944,0.0001400896,0.0003897408,0.00001047161,0.0001561823,0.0001317598],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998713,0.00002198121,0.00005554192,0.000405328,0.0001402007,0.0005734949,0.00006198459,0.00002017868,0.000008353662],"genre_scores_gemma":[0.9968114,0.0002493802,0.0001284615,0.002467802,0.0001002944,0.00004557659,0.0001174248,0.00002976223,0.00004989684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1308616,"threshold_uncertainty_score":0.6488518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01966569239590586,"score_gpt":0.293723077208798,"score_spread":0.2740573848128922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}